Document Detail


Prevention of stroke in patients with hypertension.
MedLine Citation:
PMID:  17666193     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Despite the substantial evidence of the benefits of lowering blood pressure, conventional treatment does not normalize the burden of major cardiovascular events in patients with hypertension. Data now suggest that the nature of the antihypertensive agent used may have an important impact on long-term cardiovascular outcomes, including stroke. Optimal treatment should provide powerful 24-hour blood pressure control, including during the early morning hours when the risk of stroke is highest. In addition, antihypertensive therapies selected should have positive blood pressure-independent effects on stroke risk. In contrast to angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers (ARBs) provide consistent benefits in stroke protection beyond blood pressure lowering. The ARB telmisartan has a particularly interesting profile for stroke management. Selective angiotensin II type 1 receptor blockade and 24-hour blood pressure control with telmisartan provide the potential for improved stroke prevention. This will be investigated in the Prevention Regimen for Effectively Avoiding Second Strokes (PROFESS) study.
Authors:
Björn Dahlöf
Related Documents :
2107863 - Optimal value of filling pressure in the right side of the heart in acute right ventric...
17920983 - Diagnosis and management of labile blood pressure during acute cerebrovascular accident...
8158793 - Bladder pressure sensors in an animal model.
Publication Detail:
Type:  Journal Article; Review     Date:  2007-05-25
Journal Detail:
Title:  The American journal of cardiology     Volume:  100     ISSN:  0002-9149     ISO Abbreviation:  Am. J. Cardiol.     Publication Date:  2007 Aug 
Date Detail:
Created Date:  2007-08-01     Completed Date:  2007-09-25     Revised Date:  2014-01-09    
Medline Journal Info:
Nlm Unique ID:  0207277     Medline TA:  Am J Cardiol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  17J-24J     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Angiotensin II Type 1 Receptor Blockers / administration & dosage,  therapeutic use*
Angiotensin-Converting Enzyme Inhibitors / administration & dosage,  therapeutic use*
Antihypertensive Agents / administration & dosage,  therapeutic use*
Benzimidazoles / administration & dosage,  therapeutic use*
Benzoates / administration & dosage,  therapeutic use*
Europe / epidemiology
Humans
Hypertension / complications*
Stroke / complications,  mortality,  prevention & control*
Chemical
Reg. No./Substance:
0/Angiotensin II Type 1 Receptor Blockers; 0/Angiotensin-Converting Enzyme Inhibitors; 0/Antihypertensive Agents; 0/Benzimidazoles; 0/Benzoates; U5SYW473RQ/telmisartan

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Importance of aggressive blood pressure lowering when it may matter most.
Next Document:  Rationale for double renin-angiotensin-aldosterone system blockade.